[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100642534":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":11,"centralContacts":26,"locations":32,"responsibleParty":50,"collaborators":11,"id":52,"slug":53,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":11,"eligibilityCriteria":58,"healthyVolunteers":59,"sex":60,"minAge":61,"maxAge":62,"enrollmentInfo":63,"targetDuration":11,"studyType":66,"phases":67,"briefSummary":69,"conditions":70,"keywords":73,"overallStatus":75,"whyStopped":11,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"Genrix (Shanghai) Biopharmaceutical Co., Ltd.","INDUSTRY",[8,14,17],{"label":9,"type":10,"description":11,"interventionNames":12},"GR2301 injection dose1\u002FPlacebo","EXPERIMENTAL",null,[13],"Drug: GR2301 injection",{"label":15,"type":10,"description":11,"interventionNames":16},"GR2301 injection dose2\u002FPlacebo",[13],{"label":18,"type":10,"description":11,"interventionNames":19},"GR2301 injection dose3\u002FPlacebo",[13],[21],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":11},"DRUG","GR2301 injection","IL15 monoclonal antibody",[9,15,18],[27],{"name":28,"role":29,"phone":30,"phoneExt":11,"email":31},"liaison officer","CONTACT","021-50805988-8039","shuxueye@genrixbio.com",[33],{"facility":34,"status":11,"city":35,"state":36,"zip":37,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"Beijing Tongren Hospital Affiliated to Capital Medical University","Beijing","Beijing Municipality","100730","China","CN",{"type":41,"coordinates":42},"Point",[43,44],116.39723,39.9075,{"lat":44,"lon":43},[47],{"name":48,"role":29,"phone":30,"phoneExt":11,"email":49},"Assistant project manager","liuruijun@genrixbio.com",{"type":51,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100642534","phase-1-a-clinical-trial-of-multiple-doses-of-gr2301-injection-in-healthy-adult-trial-participants-in-china-100642534",false,"NCT07647224","A Clinical Trial of Multiple Doses of GR2301 Injection in Healthy Adult Trial Participants in China.","A Randomized, Double-blind, Placebo-controlled Phase Ib Clinical Trial Evaluating the Safety, Tolerability, Pharmacokinetics, and Immunogenicity Profiles of Multiple Doses of GR2301 Injection in Healthy Adult Trial Participants in China.","Main Inclusion Criteria:\n\n1. BMI 19.0-28.0 kg\u002Fm², with male subjects weighing ≥50.0 kg and female subjects weighing ≥45.0 kg；\n2. Understand and comply with the requirements of the clinical protocol, voluntarily participate in the clinical trial, and sign the informed consent form.\n\nMain Exclusion Criteria:\n\n1. A history of past or current conditions involving the nervous system, cardiovascular system, urinary system, digestive system, respiratory system, endocrine system, metabolic system, or other clearly documented medical conditions, which the investigator deems may pose a risk to the subject's safety or interfere with the conduct, progress, or completion of the trial.\n2. History of drug use or substance abuse, or positive urine drug screening prior to enrollment.\n3. Pregnant and breastfeeding women.",true,"ALL","18 Years","45 Years",{"count":64,"type":65},36,"ESTIMATED","INTERVENTIONAL",[68],"PHASE1","This is a randomized, double-blind, placebo-controlled Phase I clinical trial evaluating the safety, tolerability, pharmacokinetics and immunogenicity characteristics of GR2301 injection in healthy adult subjects in China. The Multiple doses will be gradually escalated.",[71,72],"Multiple Dose","Healthy Adult Participants",[74],"IL15","NOT_YET_RECRUITING","2026-06-09",{"date":78,"type":79},"2026-06-15","ACTUAL",{"date":81,"type":65},"2026-06",{"date":83,"type":65},"2027-07",{"name":5,"class":6},1]